<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019630</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066924</org_study_id>
    <secondary_id>NCI-99-C-0039F</secondary_id>
    <secondary_id>LIPO-NCI-99-C-0039</secondary_id>
    <secondary_id>NCI-99-C-0039</secondary_id>
    <nct_id>NCT00019630</nct_id>
    <nct_alias>NCT00001798</nct_alias>
  </id_info>
  <brief_title>Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors</brief_title>
  <official_title>Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating&#xD;
      children who have refractory solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the tolerance to and toxicity profile of doxorubicin HCl liposome&#xD;
      (Lipodox) at standard doxorubicin doses and doses of Lipodox that were tolerable in adults&#xD;
      administered every 3 weeks in pediatric patients with refractory solid tumors.&#xD;
&#xD;
      II. Determine the maximum tolerated dose of this drug in these patients if dose-limiting&#xD;
      toxicity is observed at doses of 105 mg/m2 or less.&#xD;
&#xD;
      III. Determine the pharmacokinetics of this drug in these patients. IV. Assess the&#xD;
      cardiotoxicity of this drug in children who have previously been treated with free&#xD;
      doxorubicin and in children who have not previously received doxorubicin.&#xD;
&#xD;
      V. Evaluate the feasibility of using cardiac MRI functional imaging as a screening tool for&#xD;
      the quantitative assessment of doxorubicin-induced cardiotoxicity.&#xD;
&#xD;
      VI. Determine if serum troponin t levels are a useful biomarker for doxorubicin-induced&#xD;
      myocardial damage.&#xD;
&#xD;
      PROTOCOL OUTLINE: This is a dose-escalation, multicenter study. Patients receive doxorubicin&#xD;
      HCl liposome IV over 60 minutes. Treatment repeats every 4 weeks for a maximum of 10 courses&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 4-6 patients receive escalating doses of doxorubicin HCl liposome until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 4 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A total of 21-36 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Childhood Soft Tissue Sarcoma</condition>
  <condition>Childhood Liver Cancer</condition>
  <condition>Bone Cancer</condition>
  <condition>Brain Tumor</condition>
  <condition>Kidney Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin HCl liposome</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- Histologically confirmed solid tumor, including but not limited&#xD;
        to: Rhabdomyosarcoma and other soft tissue sarcomas Ewing's family tumors Osteosarcoma&#xD;
        Neuroblastoma Wilms' tumor Hepatic tumors Germ cell tumors Primary brain tumors&#xD;
        Histological confirmation for brain stem gliomas may be waived Refractory to standard&#xD;
        treatment and no curative therapy available Measurable or evaluable disease Evidence of&#xD;
        progressive disease on prior chemotherapy or radiotherapy or persistent disease after prior&#xD;
        surgery --Prior/Concurrent Therapy-- Biologic therapy: At least 1 week since prior&#xD;
        colony-stimulating factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin&#xD;
        alfa) At least 4 months since prior bone marrow transplantation No concurrent anticancer&#xD;
        immunotherapy Chemotherapy: See Disease Characteristics At least 3 weeks since prior&#xD;
        chemotherapy (4 weeks for nitrosoureas) and recovered Prior anthracyclines as adjuvant&#xD;
        front-line therapy allowed provided: No relapse during therapy At least 6 months since last&#xD;
        dose Cumulative dose is no greater than 400 mg/m2 for patients who received bolus&#xD;
        administration without a concurrent cardioprotectant (e.g., dexrazoxane) or received&#xD;
        cardiac irradiation and no greater than 450 mg/m2 for patients who received either&#xD;
        continuous infusion or administration with a concurrent cardioprotectant and have not&#xD;
        received cardiac irradiation No other concurrent anticancer chemotherapy Endocrine therapy:&#xD;
        Concurrent corticosteroids for brain tumor-associated edema allowed (must be on stable or&#xD;
        decreasing dose for at least 1 week prior to study) Radiotherapy: See Disease&#xD;
        Characteristics At least 4 weeks since prior radiotherapy and recovered No more than 1,500&#xD;
        cGy of prior cardiac radiotherapy No prior extensive radiotherapy (e.g., craniospinal&#xD;
        radiation, total body radiation, or radiation to more than half of the pelvis) No&#xD;
        concurrent anticancer radiotherapy Surgery: See Disease Characteristics Other: No other&#xD;
        concurrent anticancer investigational agents No other concurrent liposomal formulations of&#xD;
        any drug (e.g., liposomal amphotericin B) --Patient Characteristics-- Age: 21 and under&#xD;
        Performance status: ECOG 0-2 Life expectancy: At least 2 months Hematopoietic: Absolute&#xD;
        granulocyte count greater than 1,500/mm3 Hemoglobin greater than 8 g/dL Platelet count&#xD;
        greater than 100,000/mm3 Hepatic: Bilirubin normal SGPT no greater than 2 times upper limit&#xD;
        of normal No significant hepatic dysfunction Renal: Creatinine normal OR Creatinine&#xD;
        clearance at least 60 mL/min Cardiovascular: Cardiac ejection fraction at least 45% on MUGA&#xD;
        (National Cancer Institute patients) OR Shortening fraction at least 28% on echocardiogram&#xD;
        (Children's Hospital of Philadelphia patients) No significant or preexisting cardiac&#xD;
        dysfunction (e.g., recurrent or persistent cardiac dysrhythmia or an ejection fraction&#xD;
        below the lower limit of normal on MUGA or echocardiogram) Pulmonary: No significant&#xD;
        pulmonary dysfunction Other: Not pregnant or nursing Negative pregnancy test Fertile&#xD;
        patients must use effective contraception No clinically significant unrelated systemic&#xD;
        illness (e.g., serious infections or organ dysfunction) No allergy to doxorubicin or other&#xD;
        anthracyclines, eggs, egg products, or other liposomal drug formulations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Lowe</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2002</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>Ewing's family of tumors</keyword>
  <keyword>Wilms' tumor</keyword>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>bone cancer</keyword>
  <keyword>brain tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>central nervous system cancer</keyword>
  <keyword>childhood brain stem glioma</keyword>
  <keyword>childhood brain tumor</keyword>
  <keyword>childhood cancer</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood cerebellar astrocytoma</keyword>
  <keyword>childhood cerebral astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>childhood ependymoma</keyword>
  <keyword>childhood extracranial germ cell tumor</keyword>
  <keyword>childhood extragonadal malignant germ cell tumor</keyword>
  <keyword>childhood liver cancer</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood mature and immature teratomas</keyword>
  <keyword>childhood medulloblastoma</keyword>
  <keyword>childhood meningioma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood rhabdomyosarcoma</keyword>
  <keyword>childhood soft tissue sarcoma</keyword>
  <keyword>childhood solid tumor</keyword>
  <keyword>childhood supratentorial primitive neuroectodermal and pineal tumors</keyword>
  <keyword>childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>endocrine cancer</keyword>
  <keyword>gastrointestinal cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>kidney tumor</keyword>
  <keyword>kidney/urinary cancer</keyword>
  <keyword>liver and intrahepatic biliary tract cancer</keyword>
  <keyword>muscle cancer</keyword>
  <keyword>musculoskeletal cancer</keyword>
  <keyword>neuroblastoma</keyword>
  <keyword>osteosarcoma</keyword>
  <keyword>osteosarcoma/malignant fibrous histiocytoma of bone</keyword>
  <keyword>pediatric germ cell tumor</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Wilms' tumor</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal and pineal tumors</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent tumors of the Ewing's family</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage, Ewing's family of tumors</keyword>
  <keyword>stage, Wilms' tumor</keyword>
  <keyword>stage, childhood extracranial germ cell tumor</keyword>
  <keyword>stage, childhood liver cancer</keyword>
  <keyword>stage, childhood medulloblastoma</keyword>
  <keyword>stage, childhood rhabdomyosarcoma</keyword>
  <keyword>stage, childhood soft tissue sarcoma</keyword>
  <keyword>stage, neuroblastoma</keyword>
  <keyword>stage, osteosarcoma</keyword>
  <keyword>stage/type, childhood brain tumor</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

